EGFR Positive Lung Cancer UK

Registered charity 1189722 · accounts filings on the Charity Commission register · also known as EGFR POSITIVE UK

EGFR Positive UK works to promote the needs of EGFR mutation positive lung cancer patients across the UK.

Causes: The Advancement Of Health Or Saving Of Lives · website · Get email alerts

Latest income
£89k
Latest spending
£57k
Registered
2020
Accounts read
FY2025

Financial health, per its FY2025 accounts

The accounts state that total receipts for the year were £88,938, with a general surplus of £13,712 added to reserves. The charity holds £24,502 in bank and £70,108 in fixed deposits, while restricted funds of £18,212 are held for a specific project. The trustees report that the charity does not employ staff and has low fixed costs.

Automated summary of the FY2025 accounts; the evidenced findings below carry the verbatim passages.

What the accounts disclose

Largest income source: Fundraising (88% of income)
88% came from fundraising and an additional £ 19,169 from Gift Aid
Per its FY2025 accounts as filed with the Charity Commission.

Discloses 3 of 6 completeness components.

Public fundraising profile: JustGiving — EGFR+ (matched by registered charity number).

Public profiles (found on the charity’s own website): instagram

Trustees · trustee networks

Trustee list from the Charity Commission register (current, not historical).

Operates in: Northern Ireland · Scotland · Throughout England And Wales

Income and spending

Financial year endIncomeSpending
31/03/2025£89k£57k
31/03/2024£59k£51k
31/03/2023£23k£10k
31/03/2022£38k£1k
31/03/2021£3k£0

Common questions

Is EGFR Positive Lung Cancer UK financially healthy?

Per its FY2025 accounts: The accounts state that total receipts for the year were £88,938, with a general surplus of £13,712 added to reserves. The charity holds £24,502 in bank and £70,108 in fixed deposits, while restricted funds of £18,212 are held for a specific project. The trustees report that the charity does not employ staff and has low fixed costs.